Puma Biotechnology Inc. (PBYI)

22.58
NASDAQ : Health Technology
Prev Close 23.21
Day Low/High 22.50 / 23.27
52 Wk Low/High 17.60 / 101.50
Avg Volume 1.25M
Exchange NASDAQ
Shares Outstanding 38.13M
Market Cap 920.96M
EPS -7.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Puma - SUMMIT Poster At SABCS 2018

Puma - SUMMIT Poster At SABCS 2018

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's drug neratinib are being presented at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently...

Puma - CONTROL Poster At SABCS 2018

Puma - CONTROL Poster At SABCS 2018

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, is presenting updated results from a Phase II clinical trial of Puma's drug neratinib at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San...

Puma - ExteNET Poster At SABCS 2018

Puma - ExteNET Poster At SABCS 2018

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from the subgroup of patients with hormone receptor positive (HR-positive) breast cancer from the Company's Phase III ExteNET Trial of neratinib for early stage...

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 2, 2018 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 44,875...

PBYI January 2019 Options Begin Trading

PBYI January 2019 Options Begin Trading

Investors in Puma Biotechnology Inc saw new options become available today, for the January 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new January 2019 contracts and identified one put and one call contract of particular interest.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BERY, DLTH, DNB, ETSY, LND, MOS Downgrades: CIZN, CVV, FCX, LIND, OAS, PACW, PTVCB, STN, SYF, WAFD Initiations: CSSE, PBYI, PVG, SMPL, TRMT Read on to get TheStreet Quant Ratings' detailed report:

December 28th Options Now Available For Puma Biotechnology (PBYI)

December 28th Options Now Available For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology Inc saw new options begin trading today, for the December 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new December 28th contracts and identified one put and one call contract of particular interest.

Puma Biotechnology To Present At Credit Suisse Healthcare Conference

Puma Biotechnology To Present At Credit Suisse Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Noteworthy Friday Option Activity: PBYI, NUS, HSII

Noteworthy Friday Option Activity: PBYI, NUS, HSII

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Puma Biotechnology Inc , where a total volume of 7,141 contracts has been traded thus far today, a contract volume which is representative of approximately 714,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 82.3% of PBYI's average daily trading volume over the past month, of 867,945 shares.

Puma Biotechnology Becomes Oversold (PBYI)

Puma Biotechnology Becomes Oversold (PBYI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Puma Biotechnology Reports Third Quarter 2018 Financial Results

Puma Biotechnology Reports Third Quarter 2018 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2018.

First Week Of December 7th Options Trading For Puma Biotechnology (PBYI)

First Week Of December 7th Options Trading For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology Inc saw new options become available this week, for the December 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new December 7th contracts and identified one put and one call contract of particular interest.

Puma Biotechnology To Host Conference Call To Discuss Third Quarter Financial Results

Puma Biotechnology To Host Conference Call To Discuss Third Quarter Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.

Celcuity Announces Clinical Trial Collaboration With Puma Biotechnology And West Cancer Center

Celcuity Announces Clinical Trial Collaboration With Puma Biotechnology And West Cancer Center

Celcuity Inc. (Nasdaq: CELC), a functional cellular analysis company that is discovering new cancer subtypes and commercializing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, today...

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 9, 2018, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 18,750...

Puma Biotechnology's Licensing Partner CANbridge Pharmaceutical Submits New Drug Application For NERLYNX® (neratinib) In China

Puma Biotechnology's Licensing Partner CANbridge Pharmaceutical Submits New Drug Application For NERLYNX® (neratinib) In China

Puma Biotechnology, Inc. (Nasdaq: PBYI) has been advised that its licensing partner CANbridge Pharmaceutical Inc received confirmation that China's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for NERLYNX®...

Puma Biotechnology To Present At Cantor Global Healthcare Conference

Puma Biotechnology To Present At Cantor Global Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on September 5, 2018 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 31,125...

European Commission Grants Marketing Authorisation For Puma Biotechnology's NERLYNX® (neratinib) For Extended Adjuvant Treatment Of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer

European Commission Grants Marketing Authorisation For Puma Biotechnology's NERLYNX® (neratinib) For Extended Adjuvant Treatment Of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (Nasdaq:PBYI) announced that the European Commission (EC), has granted marketing authorisation for NERLYNX® (neratinib) for the extended adjuvant treatment of adult patients with early stage hormone receptor positive...

October 5th Options Now Available For Puma Biotechnology (PBYI)

October 5th Options Now Available For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology Inc saw new options become available today, for the October 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new October 5th contracts and identified one put and one call contract of particular interest.

Puma Biotechnology Reports Second Quarter 2018 Financial Results

Puma Biotechnology Reports Second Quarter 2018 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2018.

September 28th Options Now Available For Puma Biotechnology (PBYI)

September 28th Options Now Available For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology Inc saw new options begin trading today, for the September 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new September 28th contracts and identified one put and one call contract of particular interest.

Puma Biotechnology Files New Drug Submission For NERLYNX® In Canada

Puma Biotechnology Files New Drug Submission For NERLYNX® In Canada

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Health Canada has accepted for review the Company's New Drug Submission (NDS) for the medicinal product NERLYNX® (neratinib) for the extended adjuvant treatment of adult...

Puma Biotechnology To Host Conference Call To Discuss Second Quarter Financial Results

Puma Biotechnology To Host Conference Call To Discuss Second Quarter Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.

Puma Biotechnology And Strata Oncology Announce Collaboration To Accelerate Enrollment In Neratinib HER2 Mutation Basket Study (SUMMIT Trial)

Puma Biotechnology And Strata Oncology Announce Collaboration To Accelerate Enrollment In Neratinib HER2 Mutation Basket Study (SUMMIT Trial)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, and Strata Oncology, Inc.

Puma Biotechnology Receives Positive CHMP Opinion Recommending Approval Of NERLYNX® For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology Receives Positive CHMP Opinion Recommending Approval Of NERLYNX® For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that on June 28, 2018 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorisation for the medicinal product NERLYNX® (neratinib) for the...

Puma Biotechnology Announces Results Of CHMP Reexamination Of MAA For Neratinib For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology Announces Results Of CHMP Reexamination Of MAA For Neratinib For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive trend vote recommending the approval of the Marketing Authorisation Application...

NSABP FB-10: Phase IB Dose-Escalation Study Evaluating The Combination Of Trastuzumab Emtansine (T-DM1) With Neratinib In Women With Metastatic HER2-Positive Breast Cancer (Graphic: Business Wire)

NSABP FB-10: Phase IB Dose-Escalation Study Evaluating The Combination Of Trastuzumab Emtansine (T-DM1) With Neratinib In Women With Metastatic HER2-Positive Breast Cancer (Graphic: Business Wire)

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that interim results from the Phase Ib/II FB-10 clinical trial of Puma's investigational drug PB272 (neratinib) given in combination with the antibody drug conjugate T-DM1...

TheStreet Quant Rating: D- (Sell)